NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells

[31] Ellison DW(2015)Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis PLoS ONE 125 424-8959

[32] Stupp R(2013)Memantine transport across the mouse blood-brain barrier is mediated by a cationic influx H+ antiporter Mol Pharm 35 230-89

[33] Mason WP(2019)Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma Cancer 14 1245-13

[34] van den Bent MJ(2015)The dichotomy of memantine treatment for ischemic stroke: dose-dependent protective and detrimental effects J Cereb Blood Flow Metab 305 48-4021

[35] Weller M(2011)High-frequency field stimulation of primary neurons enhances ryanodine receptor-mediated Ca2+ release and generates hydrogen peroxide, which jointly stimulate NF-κB activity Antioxid Redox Signal 131 8-339

[36] Fisher B(2003)The novel neuroprotective action of sulfasalazine through blockade of NMDA receptors J Pharmacol Exp Ther 67 8952-undefined

[37] Taphoorn MJB(2004)Nuclear factor-kappa B p65 in NMDA-induced retinal neurotoxicity Brain Res Mol Brain Res 428 77-undefined

[38] Belanger K(2007)Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase Can Res 6 9-undefined

[39] Brandes AA(2018)Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression Cancer Lett 78 4007-undefined

[40] Marosi C(2011)Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production PLoS ONE 18 329-undefined

[31] Ellison DW(2015)Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis PLoS ONE 125 424-8959

[32] Stupp R(2013)Memantine transport across the mouse blood-brain barrier is mediated by a cationic influx H+ antiporter Mol Pharm 35 230-89

[33] Mason WP(2019)Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma Cancer 14 1245-13

[34] van den Bent MJ(2015)The dichotomy of memantine treatment for ischemic stroke: dose-dependent protective and detrimental effects J Cereb Blood Flow Metab 305 48-4021

[35] Weller M(2011)High-frequency field stimulation of primary neurons enhances ryanodine receptor-mediated Ca2+ release and generates hydrogen peroxide, which jointly stimulate NF-κB activity Antioxid Redox Signal 131 8-339

[36] Fisher B(2003)The novel neuroprotective action of sulfasalazine through blockade of NMDA receptors J Pharmacol Exp Ther 67 8952-undefined

[37] Taphoorn MJB(2004)Nuclear factor-kappa B p65 in NMDA-induced retinal neurotoxicity Brain Res Mol Brain Res 428 77-undefined

[38] Belanger K(2007)Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase Can Res 6 9-undefined

[39] Brandes AA(2018)Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression Cancer Lett 78 4007-undefined

[40] Marosi C(2011)Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production PLoS ONE 18 329-undefined